Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Incresed Revenue, Narrowed Losses in Q3

NEW YORK, Oct. 31 (GenomeWeb News) - Ciphergen Biosystems reported a decline in net losses of 34 percent year-over-year in its report on third quarter earnings released late yesterday afternoon.

 

Losses totaled $5.2 million, compared with $7.9 million in the year-ago period. Revenues also rose sharply at 57 percent, from $10.2 million in the third quarter of 2002 to $16.1 million in the quarter just ended. Ciphergen attributed this revenue increase to increased sales of its ProteinChip systems, automation products, and BioSepra process proteomics products. The company said in the report that it expected fourth quarter revenue to continue to rise to $19 million, and that it expected 2004 revenue to increase approximately 45 to 55 percent over 2003 total revenues.

 

The company's R&D spending dropped in the third quarter, to $5.4 million from $6 million in the year-ago period.

 

As of Sept. 30, 2003, Ciphergen said it had $49.3 million in cash, cash equivalents, and investments.

 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.